中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

26 records (took 0.044 seconds)

    Method for producing amide compound
    11.
    发明授权
    Method for producing amide compound 有权
    酰胺化合物的制备方法

    公开(公告)号：US08816069B2

    公开(公告)日：2014-08-26

    申请号：US13635092

    申请日：2011-03-15

    Applicant: Junichi Kugimoto ,  Joji Kawai ,  Hiroshi Matsumoto

    Inventor： Junichi Kugimoto ,  Joji Kawai ,  Hiroshi Matsumoto

    IPC: C07D225/02 ,  C07D201/04 ,  C07D201/06

    CPC classification number: C07D201/06 ,  C07D201/04 ,  C07D225/02

    Abstract: The present invention relates to a method for producing a high purity, high quality amide compound, particularly, lactam. A first embodiment of the present invention is characterized in that an amount of each of a halide, an aldehyde compound, an alcohol compound and a nitrile compound contained in a solution recycled into an oxime-forming step is controlled to an amount of 0.4 mol % or less based on the ketone as a starting material. A second embodiment of the present invention is characterized in that one or more compounds selected from the group consisting of a ketone, an oxime and an amide compound are purified by hydrogenation and/or crystallization for eliminating impurities containing a double bond. A third embodiment of the present invention is characterized in that a content of impurities having a cyclic bridge structure is controlled by using a cycloalkanone purified by recrystallization.

    Abstract translation: 本发明涉及一种生产高纯度，优质酰胺化合物，特别是内酰胺的方法。 本发明的第一实施方案的特征在于，将再循环到肟形成步骤的溶液中所含的卤化物，醛化合物，醇化合物和腈化合物中的每一种的量控制为0.4mol％ 基于酮作为原料。 本发明的第二个实施方案的特征在于，通过氢化和/或结晶纯化一种或多种选自酮，肟和酰胺化合物的化合物，以消除含有双键的杂质。 本发明的第三实施方案的特征在于通过使用通过重结晶纯化的环烷酮来控制具有环状桥结构的杂质的含量。

    Ammonium Sulphate Production on Industrial Scale
    14.
    发明申请
    Ammonium Sulphate Production on Industrial Scale 有权

    公开(公告)号：US20230054797A1

    公开(公告)日：2023-02-23

    申请号：US17796631

    申请日：2021-02-04

    Applicant: CAP III B.V.

    Inventor： Johan Thomas Tinge ,  Jarno Martijn Westerhof ,  Olaf Poorter

    IPC: C01C1/242 ,  C07D201/06 ,  C07D201/16

    Abstract: The invention provides a process for the production of crystalline ammonium sulfate, wherein the process comprises performing a Beckmann rearrangement reaction, neutralizing the Beckmann rearrangement reaction mixture, separating a first aqueous ammonium sulfate phase and an aqueous ε-caprolactam phase, charging the first ammonium sulfate phase to a first evaporative type crystallization section wherein crystalline ammonium sulfate is obtained, discharging from the first evaporative type crystallization section mother liquor enriched in organic components, extracting the aqueous ε-caprolactam phase to obtain an extracted ε-caprolactam phase and a second aqueous ammonium sulfate phase, discharging the mother liquor that is discharged from the first evaporative type crystallization section and/or the second aqueous ammonium sulfate phase to a second evaporative type crystallization section wherein evaporative type crystallization is performed so that a three-phase system occurs. At least a liquid oily phase is recovered from the three-phase system. The invention further provides a plant suitable to carry out the process of the invention, crystalline ammonium sulfate and a liquid oily phase obtained by the process of the invention.

    Substituted naphthyridinyl hydrazines as anti-liver cancer agents
    17.
    发明授权
    Substituted naphthyridinyl hydrazines as anti-liver cancer agents 有权

    公开(公告)号：US09855255B1

    公开(公告)日：2018-01-02

    申请号：US15607397

    申请日：2017-05-26

    Applicant: KING SAUD UNIVERSITY

    Inventor： Nagy Mahmoud Hassan Khalifa ,  Mohamed A. Al-Omar ,  Abd El-Galil E. Amr

    IPC: C07D201/06 ,  A61K31/15 ,  A61K31/4375

    CPC classification number: A61K31/4375 ,  C07D201/06

    Abstract: The substituted naphthyridinyl hydrazine compounds as anti-liver cancer agents are anti-liver cancer agents that inhibit proliferative pathways of cancer cells, thereby exhibiting potent in vitro and in vivo anticancer activity. The compounds have the formula: wherein R1 and R2 each are selected independently from hydrogen, mercapto, and C1-C5-alkyl, preferably methyl, ethyl, propyl, isopropyl or halogen; R3 and R4 each are selected independently from hydrogen, alkyl or halogen; and R5 is selected from substituted or unsubstituted aryl, more preferably from substituted phenyl, naphthyl, and substituted or unsubstituted heteroaryl, more preferably from furyl, pyrrolyl, thienyl, imidazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, benzothiazolyl, oxadiazolyl or sugar moities. These agents exert their action through topoisomerase II inhibition.

Patent Agency Ranking